BioCentury | Jun 11, 2020
Deals

Prism’s peptide mimetic platform finds second discovery partner

...a REST inhibitor for an undisclosed CNS indication. Targets CTNNB1 - β-catenin CREBBP (CBP) - CREB...
BioCentury | Dec 20, 2019
Financial News

Forma’s $100M series D cements pivot from discovery shop to heme and cancer therapeutics

...funds managed by Janus Henderson Investors and an undisclosed healthcare investment fund. Targets: CBP - CREB...
BioCentury | Jun 20, 2019
Emerging Company Profile

Casma: Tailoring autophagy targets to indications

...Louis, Mo. Targets BECN1 (ATG6) - Beclin-1 TFEB - Transcription factor EB TORC1 (CRTC1) - CREB...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

...lines, a small molecule modulator of the CH1 domain of E1A binding protein p300 (EP300; p300)/CREB...
BioCentury | May 18, 2018
Finance

CellCentric’s magic trio

...the clinic.” West said the dual inhibitor of E1A binding protein p300 (EP300; p300) and CREB...
...$6 million through a combination of government funding and target discovery deals. Virginia Li, Assistant Editor CCS1477 CellCentric Ltd. CREB...
BioCentury | May 18, 2018
Financial News

CellCentric raises $26M to advance into the clinic

...hematological cancers. CCS1477 is a dual inhibitor of E1A binding protein p300 (EP300; p300) and CREB...
BioCentury | May 14, 2018
Financial News

CellCentric raises $26M to advance into the clinic

...hematological cancers. CCS1477 is a dual inhibitor of E1A binding protein p300 (EP300; p300) and CREB...
BioCentury | Jan 23, 2018
Distillery Therapeutics

Cancer

...optimizing the peptide for use in patients. TARGET/MARKER/PATHWAY: v-myb myeloblastosis viral oncogene homolog (MYB; c-myb); CREB...
...CONTACT: Alex Kentsis, Memorial Sloan Kettering Cancer Center, New York, N.Y. email: kentsisresearchgroup@gmail.com Hongjiang Li Sloan Kettering Institute CREB...
BioCentury | Jan 5, 2018
Financial News

resTORbio proposes $85M IPO

...raised to $65 million (see BioCentury, Dec. 1, 2017 ). resTORbio Inc., Boston, Mass. Jennie Walters RTB101 resTORbio Inc. CREB...
BioCentury | Dec 21, 2017
Preclinical News

New pathway could overcome resistance to TKIs in cancer

...Conversely, deleting genes associated with transcriptional complexes -- including E1A binding protein p300 (EP300; p300), CREB...
...dependent kinase 7 (CDK7) and CDK12. Jennie Walters erlotinib Tarceva Astellas Pharma Inc. Broad Institute of MIT and Harvard Dana-Farber Cancer Institute Harvard CREB...
Items per page:
1 - 10 of 70